Home
Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

Impacting News July 26, 2022

Seagen, Astellas Pharma & Merck Collaboration
Seagen (SGEN) and Astellas Pharma (ALPMY) have entered a clinical collaboration . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
, ,
July 26, 2022

Other Articles